Fredun Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 539730 | NSE: | Pharmaceuticals & Drugs | Small Cap

Fredun Pharma Share Price

672 -21.45 -3.09%
as on 21-Nov'24 16:59

DeciZen - make an informed investing decision on Fredun Pharma

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Undervalued

3. Price Trend

Fredun Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (SA):
18.51
Market Cap:
327.4 Cr.
52-wk low:
650
52-wk high:
1,054

Is Fredun Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Fredun Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Fredun Pharmaceuticals Ltd is a average quality company.

2. Is Fredun Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Fredun Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Fredun Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Fredun Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Fredun Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Fredun Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 14.2%24.7%18.2%15.9%20.6%10.4%9.5%13.2%17.6%17.1%-
Value Creation
Index
0.00.80.30.10.5-0.3-0.3-0.10.30.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 25.342.356.759.697113134224275348388
Sales YoY Gr.-67.1%34%5%62.9%16.2%18.7%67.7%22.4%26.8%-
Adj EPS 1.34.43.54.911.54.44.912.421.632.237.5
YoY Gr.-238.9%-20.7%38.4%136.6%-62.2%13.3%151.6%73.5%49.3%-
BVPS (₹) 11.515.720.164.797.7103.6108153.1194.3255.2277.2
Adj Net
Profit
0.31.10.81.74.61.725.59.815.118
Cash Flow from Ops. 1.83.3417.30.8-10.60.2-2.4-14.4-0.4-
Debt/CF from Ops. 5.14.74.60.623.1-3.3233.3-22.2-6-240.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 33.8%29.1%37.5%26.8%
Adj EPS 42.7%22.8%86.8%49.3%
BVPS41.1%21.2%33.2%31.3%
Share Price - 24.9% 13.4% -21.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
10.429.714.811.3154.34.79.911.913.914.1
Op. Profit
Mgn %
6.79.869.610.57.476.210.110.911.9
Net Profit
Mgn %
1.22.51.52.84.71.51.52.53.64.34.6
Debt to
Equity
3.13.92.50.50.50.80.90.810.90.1
Working Cap
Days
167174200261230290324230244248113
Cash Conv.
Cycle
182812-31159811110013514936

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 14.10%

Sales growth is growing at healthy rate in last 3 years 37.51%

Net Profit is growing at healthy rate in last 3 years 86.76%

Debt to equity has declined versus last 3 years average to 0.88

Sales growth is good in last 4 quarters at 29.11%

No data to display

Latest Financials - Fredun Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 37.5 -
TTM Sales (₹ Cr.) 388 -
BVPS (₹.) 277.2 -
Reserves (₹ Cr.) 126 -
P/BV 2.50 -
PE 18.51 -
From the Market
52 Week Low / High (₹) 650.00 / 1054.00
All Time Low / High (₹) 12.50 / 1428.00
Market Cap (₹ Cr.) 327
Equity (₹ Cr.) 4.7
Face Value (₹) 10
Industry PE 43

Management X-Ray of Fredun Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Fredun Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales2542576097113134224275348
Operating Expenses 2438535487104125211247310
Manufacturing Costs21117377681115
Material Costs151925406082102177209261
Employee Cost 3455899111212
Other Costs 45761278151622
Operating Profit 24361089142838
Operating Profit Margin (%) 6.5%9.2%5.9%9.6%10.3%7.4%7.0%6.2%10.1%10.9%
Other Income 0120111221
Interest 12223445914
Depreciation 1111122234
Exceptional Items 000000-1000
Profit Before Tax 122362391821
Tax 0111211276
Profit After Tax 011242261116
PAT Margin (%) 1.0%2.5%2.5%2.9%4.6%1.7%1.5%2.8%3.9%4.5%
Adjusted EPS (₹)1.14.55.44.211.24.85.114.323.833.3
Dividend Payout Ratio (%)0%13%11%14%6%14%14%5%3%2%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 347223941436888120
Share Capital 3353444455
Reserves 012193537396384115
Minority Interest0000000000
Debt81315101935405383100
Long Term Debt3670111129421513
Short Term Debt5781092311116887
Trade Payables7162339344660495963
Others Liabilities 510118131919182725
Total Liabilities 23435679105141162187257308

Fixed Assets

Gross Block13212825353738425263
Accumulated Depreciation5679468101316
Net Fixed Assets8152116313130323947
CWIP 10011000000
Investments 0000000001
Inventories41071841506846150175
Trade Receivables5112015183941903565
Cash Equivalents 1111131231
Others Assets46817141821163019
Total Assets 23435679105141162187257308

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 234171-110-2-140
PBT 122262291721
Adjustment 122326981217
Changes in Working Capital 0-0-013-7-19-10-19-44-39
Tax Paid 0000000000
Cash Flow From Investing Activity -3-6-7-8-5-1-1-4-9-8
Capex -2-7-3-1-16-1-1-4-9-8
Net Investments 0000000000
Others -11-4-71100000
Cash Flow From Financing Activity 133-8414-17256
Net Proceeds from Shares 052-1100000
Net Proceeds from Borrowing 000-47118137-3
Interest Paid -1-2-2-2-3-4-4-5-9-14
Dividend Paid 0000000000
Others 202-1017-14-12822
Net Cash Flow 01-1102-211-2
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)9.6833.4633.8813.0214.594.744.7711.4213.8615.03
ROCE (%)14.2324.6718.1615.920.5610.369.5313.1517.6417.13
Asset Turnover Ratio1.251.281.140.881.050.920.881.291.241.23
PAT to CFO Conversion(x)N/A348.50.25-5.50-0.33-1.270
Working Capital Days
Receivable Days627210210962921091078352
Inventory Days5763557811114816193131170
Payable Days1442232902852211781901129485

Fredun Pharmaceuticals Ltd Stock News

Fredun Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Fredun Pharma on 21-Nov-2024 16:59 is ₹672.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Fredun Pharma stood at ₹327.4.
The latest P/E ratio of Fredun Pharma as of 21-Nov-2024 16:59 is 18.51.
The latest P/B ratio of Fredun Pharma as of 21-Nov-2024 16:59 is 2.50.
The 52-week high of Fredun Pharma is ₹1,054 and the 52-week low is ₹650.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fredun Pharma is ₹388.3 ( Cr.) .

About Fredun Pharmaceuticals Ltd

No data to display
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.